Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Johnson

Showing results (161-170 of 221) with videos related to

Pageof 23
Sort By:
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2004
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013
Physician and stakeholder perceptions of conflict of interest policies in oncologyA Craig Lockhart, Marcia S Brose, Edward S Kim, et al.
JCO Oncology Practice|April 14, 2020
Physician Practice Variability in the Use of Extended-Fraction Radiation Therapy for Bone Metastases: Are We Choosing Wisely?Arjun Gupta, Peiqi Wang, Ramy Sedhom, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancerSteven M Keller, Mark G Vangel, Henry Wagner, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy, Sarah Temin, Mark R Somerfield, et al.
Clinical Lung Cancer|June 6, 2025
Mortality in a Diverse, Real-World Lung Cancer Screening CohortMary E Gwin, Tanushree Prasad, Urooj Wahid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch, Dorothy J Giroux, Michael J Kraut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2003
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003David G Pfister, David H Johnson, Christopher G Azzoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2010
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancerMing-Sound Tsao, Akira Sakurada, Keyue Ding, et al.
Pageof 23

Showing results (161-170 of 221) with videos related to

Sort By:
Pageof 23
The Journal of Thoracic and Cardiovascular Surgery|June 30, 2004
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2013
Physician and stakeholder perceptions of conflict of interest policies in oncologyA Craig Lockhart, Marcia S Brose, Edward S Kim, et al.
JCO Oncology Practice|April 14, 2020
Physician Practice Variability in the Use of Extended-Fraction Radiation Therapy for Bone Metastases: Are We Choosing Wisely?Arjun Gupta, Peiqi Wang, Ramy Sedhom, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancerSteven M Keller, Mark G Vangel, Henry Wagner, et al.
The Oncologist|March 28, 2025
Incidence and correlates of high-grade chemotherapy-induced peripheral neuropathy in patients with lung cancerMitchell S von Itzstein, Sawsan Rashdan, Suzanne E Dahlberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy, Sarah Temin, Mark R Somerfield, et al.
Clinical Lung Cancer|June 6, 2025
Mortality in a Diverse, Real-World Lung Cancer Screening CohortMary E Gwin, Tanushree Prasad, Urooj Wahid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)Valerie W Rusch, Dorothy J Giroux, Michael J Kraut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2003
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003David G Pfister, David H Johnson, Christopher G Azzoli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 26, 2010
Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancerMing-Sound Tsao, Akira Sakurada, Keyue Ding, et al.
Pageof 23